Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Invitrogen ProtoArray technology ‘identifies’ ovarian cancer before it spreads

Invitrogen ProtoArray technology ‘identifies’ ovarian cancer before it spreads

19th November 2007

Invitrogen has revealed the publication of a study recognising the ability of the firm’s ProtoArray technology to identify auto-antigens associated with ovarian cancer.

In experiments documented in the journal of Proceedings of National Academy of Sciences (PNAS), samples from 30 ovarian cancer patients and 30 healthy subjects were profiled on Invitrogen’s ProtoArray protein microarrays.

From this data, scientists found over 94 candidate bio-markers that exhibited enhanced reactivity in cancer patients compared to healthy subjects.

"Not only are auto-antibodies well-known biomarkers in autoimmune diseases such as lupus or multiple sclerosis, but they have been shown in a range of cancers," said Paul Predki, vice-president of protein analysis at Invitrogen.

"Protein microarrays provide a rapid and sensitive platform for the screening of auto-antibodies," he added, pointing out that the new study validates ProtoArray as a "powerful technology" that scientists can use to discover new markers that indicate whether a patient has a disease or how it may have progressed.

Kip Miller, senior vice-president of bio-discovery at the life science technologies specialist, concluded that there is a "clear need" to find biological markers that indicate the presence of ovarian cancer.ADNFCR-1050-ID-18359803-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.